

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following side effects was the most common Grade 3 or higher adverse event observed with capivasertib in the Phase III CAPItello-291 trial?
  - a. Diarrhea
  - b. Hyperglycemia
  - c. Stomatitis
  - d. Rash
2. Which therapy yielded the greatest reduction in the risk of disease progression or death among the overall population in the Phase III EMBER-3 trial of imlunestrant as monotherapy or combined with abemaciclib versus standard endocrine therapy for patients with ER-positive, HER2-negative advanced breast cancer pretreated with endocrine therapy?
  - a. Standard endocrine therapy
  - b. Imlunestrant monotherapy
  - c. Imlunestrant and abemaciclib
  - d. Imlunestrant monotherapy and imlunestrant with abemaciclib yielded similar benefits
3. Trastuzumab deruxtecan has demonstrated robust intracranial activity in patients with HER2-positive metastatic breast cancer with ...
  - a. Treated or stable brain metastases
  - b. Untreated or active brain metastases
  - c. Both a and b
  - d. Neither a nor b
4. What was the approximate reduction in the risk of disease progression or death with datopotamab deruxtecan compared to investigator's choice of chemotherapy for patients with previously treated HR-positive, HER2-negative breast cancer in the Phase III TROPION-Breast01 study?
  - a. 12%
  - b. 37%
  - c. 68%
5. The Phase III INAVO120 study investigated the efficacy of inavolisib with palbociclib and fulvestrant for patients with HR-positive, HER2-negative locally advanced/metastatic breast cancer with which of the following mutations?
  - a. BRCA
  - b. AKT
  - c. ESR1
  - d. PIK3CA